Adjuvant therapy for colon cancer: Small steps toward precision medicine
Mené sur 1 729 patients atteints d'un cancer colorectal, cette étude évalue l'intérêt d'un algorithme de classification en sous-types moléculaires pour prédire le bénéfice de l'oxaliplatine en traitement adjuvant
In current practice, the choice of which adjuvant therapy to use for colon cancer is determined mainly on the basis of the patient’s TNM stage. Patients with stage III cancers are most commonly considered candidates for a fluoropyrimidine plus oxaliplatin treatment; those with stage II cancers, for a fluoropyrimidine alone or no postsurgical therapy...